Nasdaq Zy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Octant doubles its initial investment in Zymergen’s Automation Technology to significantly increase the scale and throughput of its drug discovery...

Zymergen Inc. (NASDAQ:ZY – Get Rating) has received a consensus recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 12 month price target among analysts that have […]

Zymergen (NASDAQ:ZY – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Zymergen Inc. is a biofacturing company. It design, develop and manufacture bio-based breakthrough products. Zymergen Inc. is based in EMERYVILLE, […]

Zymergen (NASDAQ:ZY – Get Rating) and National Research (NASDAQ:NRC – Get Rating) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Valuation and Earnings This table compares Zymergen and National […]

Zymergen (NASDAQ:ZY – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its rivals? We will compare Zymergen to related businesses based on the strength of its profitability, risk, valuation, analyst recommendations, earnings, institutional ownership and dividends. Insider and Institutional Ownership 48.8% […]